Reset
Id
Protein
PTM type
Site
Species
Disease
Cell line
Drug
Regulatory
Confidence score(level)
Ref.
acc1601 CYLD phosphorylation Ser418 human Lymphoma HBL-1 acalabrutinib (ACP-196) Associated 4.0 (Moderate) 33827598
acc1602 CYLD phosphorylation Ser418 human Lymphoma OCI-Ly10 acalabrutinib (ACP-196) Associated 4.0 (Moderate) 33827598
acc1603 CYLD phosphorylation Ser418 human Lymphoma HBL-1 Rituximab Impairing 5.0 (High) 33827598
acc1604 CYLD phosphorylation Ser418 human Lymphoma OCI-Ly10 Rituximab Impairing 5.0 (High) 33827598
acc1605 DDR1 phosphorylation Tyr792 human Colorectal Cancer HCT116 Dapagliflozin Associated 4.0 (Moderate) 31979355
acc1606 ERK1 phosphorylation Tyr204 human Bladder Cancer UM-UC-6 Dacomitinib Associated 4.0 (Moderate) 24166682
acc1607 ERK1 phosphorylation Thr202 human Bladder Cancer UM-UC-6 Dacomitinib Associated 4.0 (Moderate) 24166682
acc1608 EGFR phosphorylation Tyr1068 human Bladder Cancer UM-UC-6 Dacomitinib Associated 4.0 (Moderate) 24166682
acc1609 EGFR phosphorylation Tyr1068 human Bladder Cancer UM-UC-9 Dacomitinib Associated 4.0 (Moderate) 24166682
acc1610 EGFR phosphorylation Tyr1068 human Bladder Cancer UM-UC-9 Dacomitinib Associated 4.0 (Moderate) 24166682
acc1611 STAT3 phosphorylation Tyr705 human Mucoepidermoid Carcinoma UM-HMC-1 Tocilizumab Associated 4.0 (Moderate) 26287605
acc1612 STAT3 phosphorylation Tyr705 human Mucoepidermoid Carcinoma UM-HMC-3A Tocilizumab Associated 4.0 (Moderate) 26287605
acc1613 STAT3 phosphorylation Tyr705 human Mucoepidermoid Carcinoma UM-HMC-3B Tocilizumab Associated 4.0 (Moderate) 26287605
acc1614 STAT3 phosphorylation Tyr705 human Colorectal Cancer HCT116 Auranofin + ICG-001 Associated 4.0 (Moderate) 34900688
acc1615 STAT3 phosphorylation Tyr705 human Colorectal Cancer SW480 Auranofin + ICG-001 Associated 4.0 (Moderate) 34900688
acc1616 STAT3 phosphorylation Tyr705 human Colorectal Cancer DLD-1 Auranofin + ICG-001 Associated 4.0 (Moderate) 34900688
acc1617 EGFR phosphorylation Tyr1173 human Lung Cancer HCC827 Erlotinib Associated 4.0 (Moderate) 27612423
acc1618 EGFR phosphorylation Tyr1173 human Lung Cancer NCI-H3255 Erlotinib Associated 4.0 (Moderate) 27612423
acc1619 EGFR phosphorylation Tyr1173 human Lung Cancer NCI-H1975 Erlotinib Associated 4.0 (Moderate) 27612423
acc1620 EGFR phosphorylation Tyr1068 human Lung Cancer Erlotinib Enhancing 5.0 (High) 26247735
acc1621 EGFR phosphorylation Tyr1068 human Lung Cancer CL1-5 Curcumin Associated 4.0 (Moderate) 21858220
acc1622 EGFR phosphorylation Tyr1068 human Lung Cancer A549 Curcumin Associated 4.0 (Moderate) 21858220
acc1623 EGFR ubiquitination unclear human Lung Cancer A549 Gefitinib Enhancing 5.0 (High) 21858220
acc1624 EGFR ubiquitination unclear human Lung Cancer H1975 Gefitinib Enhancing 5.0 (High) 21858220
acc1625 EGFR phosphorylation Tyr1068 human Lung Cancer H1975 Curcumin Associated 4.0 (Moderate) 21858220
acc1626 EGFR ubiquitination unclear human Lung Cancer CL1-5 Curcumin Associated 4.0 (Moderate) 21858220
acc1627 EGFR ubiquitination unclear human Lung Cancer A549 Curcumin Associated 4.0 (Moderate) 21858220
acc1628 EGFR ubiquitination unclear human Lung Cancer H1975 Curcumin Associated 4.0 (Moderate) 21858220
acc1629 EGFR phosphorylation Tyr1068 human Lung Cancer CL1-5 Gefitinib Impairing 5.0 (High) 21858220
acc1630 EGFR phosphorylation Tyr1068 human Lung Cancer A549 Gefitinib Impairing 5.0 (High) 21858220
acc1631 EGFR phosphorylation Tyr1068 human Lung Cancer H1975 Gefitinib Impairing 5.0 (High) 21858220
acc1632 EGFR ubiquitination Tyr1068 human Lung Cancer CL1-5 Gefitinib Enhancing 5.0 (High) 21858220
acc1633 EGFR phosphorylation Tyr1068 human Lung Cancer PC9 Docetaxel + Gefitinib Associated 4.0 (Moderate) 24682085
acc1634 EGFR phosphorylation Tyr1068 human Head and Neck Cancer Lysophosphatidic acid (LPA) Associated 4.0 (Moderate) 12414665
acc1635 ERK1 phosphorylation Thr202 human Ovarian Cancer SK-OV-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1636 ERK1 phosphorylation Thr202 human Ovarian Cancer SK-BR-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1637 ERK1 phosphorylation Tyr204 human Ovarian Cancer SK-OV-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1638 ERK1 phosphorylation Tyr204 human Ovarian Cancer SK-BR-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1639 ERK2 phosphorylation Thr185 human Ovarian Cancer SK-OV-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1640 ERK2 phosphorylation Thr185 human Ovarian Cancer SK-BR-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1641 ERK2 phosphorylation Tyr187 human Ovarian Cancer SK-OV-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1642 ERK2 phosphorylation Tyr187 human Ovarian Cancer SK-BR-3 DpdtC Associated 4.0 (Moderate) 29467385
acc1643 ERK1 phosphorylation Thr202 human Lung Cancer H1666 Gefitinib Impairing 5.0 (High) 22777356
acc1644 ERK1 phosphorylation Tyr204 human Lung Cancer H1666 Gefitinib Impairing 5.0 (High) 22777356
acc1645 ERK2 phosphorylation Thr185 human Lung Cancer H1666 Gefitinib Impairing 5.0 (High) 22777356
acc1646 ERK2 phosphorylation Tyr187 human Lung Cancer H1666 Gefitinib Impairing 5.0 (High) 22777356
acc1647 STAT3 phosphorylation Tyr705 human Lung Cancer PC9GR Gefitinib Impairing 5.0 (High) 31671073
acc1648 STAT3 phosphorylation Tyr705 human Lung Cancer PC9GR Osimertinib Impairing 5.0 (High) 31671073
acc1649 EGFR phosphorylation Tyr1068 human Pancreas Cancer L3.6pl Gefitinib Associated 4.0 (Moderate) 16585207
acc1650 AKT phosphorylation Ser473 human Pancreas Cancer L3.6pl Gefitinib Associated 4.0 (Moderate) 16585207